Clinical Lymphoma Myeloma & Leukemia Template
Write in a clean editor, then format for Clinical Lymphoma Myeloma & Leukemia in one click — DocuGuru applies the official Elsevier template with numbered references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
About the Clinical Lymphoma Myeloma & Leukemia format
Clinical Lymphoma Myeloma & Leukemia is a peer-reviewed journal published by Elsevier, covering Multiple Myeloma Research and Treatments, Chronic Lymphocytic Leukemia Research, Lymphoma Diagnosis and Treatment.
| Publisher | Elsevier |
|---|---|
| Reference style | Numbered (Elsevier) Numbered — [1], [2] in the text [1] A. Smith, B. Jones, C. Lee, A representative article title, Clinical Lymphoma Myeloma & Leukemia 12 (2023) 45–58.
Formats any DOI in Clinical Lymphoma Myeloma & Leukemia style. No sign-up. |
| Publishes research in | Multiple Myeloma Research and Treatments Chronic Lymphocytic Leukemia Research Lymphoma Diagnosis and Treatment Acute Myeloid Leukemia Research Chronic Myeloid Leukemia Treatments |
| ISSN | 2152-2650 |
| Citation impact (2-yr) | 0.34 |
| h-index | 66 |
| i10-index | 1,372 |
| Total citations | 45,894 |
| Article processing charge | $3,670 |
| Top institutions publishing here | The University of Texas MD Anderson Cancer Center |
| Journal website | www.clinical-lymphoma-myeloma-leukemia.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Papers published in Clinical Lymphoma Myeloma & Leukemia per year
Citation impact of Clinical Lymphoma Myeloma & Leukemia by publication year
Citations each year’s papers have accumulated so far — the most recent years are still building up.
Most-cited papers in Clinical Lymphoma Myeloma & Leukemia
BackgroundIn the phase III CASTOR study in relapsed or refractory multiple myeloma, daratumumab, bortezomib, and dexamethasone (D-Vd) demonstrated significant clinical benefit versus Vd alone. Outcomes after 40.0 months of median follow-up are discussed.Patients and MethodsEligible patients had received ≥ 1 line of treatment and were administered bortezomib (1.3 mg/m2) and dexamethasone (20 mg) for 8…